1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders.
Still, even the most successful companies experience setbacks from time to time, and this biotech is no exception. So let's learn about what just happened, why it matters, and what this player is going to focus on to keep growing in the long term in light of everything else.
As well-informed investors know, CRISPR Therapeutics wouldn't be what it is today without the help of collaboration partner and benefactor Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex chipped in to cover 60% of the costs associated with developing and commercializing CRISPR's recently approved gene therapy Casgevy, and it also paid the biotech $900 million in 2021.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.85 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.84%.
